Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Patent
1995-06-07
1999-11-02
Hutzell, Paula K.
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
5303889, 53038885, 5303891, 5303898, 530402, 546 22, 546 23, C07K 1600, C07K 100, C07F 906
Patent
active
059773146
ABSTRACT:
This invention provides compounds which are analogs to the hydrolysis transition-state of a cocaine benzoyl ester group. This invention also provides such analogs linked to carrier proteins, and antibodies thereto. This invention further provides pharmaceutical composition for decreasing concentration in a subject using the antibodies produced.
REFERENCES:
patent: 3884898 (1975-05-01), Schneider
patent: 3888866 (1975-06-01), Leute et al.
patent: 3917582 (1975-11-01), Soffer et al.
patent: 3975237 (1976-08-01), Rubenstein et al.
patent: 4045420 (1977-08-01), Soffer et al.
patent: 4197237 (1980-04-01), Leute et al.
patent: 4203802 (1980-05-01), Rubenstein et al.
patent: 4220722 (1980-09-01), Rowley et al.
patent: 4235864 (1980-11-01), Kaul et al.
patent: 4493795 (1985-01-01), Nestor, Jr. et al.
patent: 4620977 (1986-11-01), Strahilevitz
patent: 4650771 (1987-03-01), Buckler et al.
patent: 4659567 (1987-04-01), Tramontano et al.
patent: 4695624 (1987-09-01), Marburg et al.
patent: 4714676 (1987-12-01), Keyes
patent: 4792446 (1988-12-01), Kim et al.
patent: 4888281 (1989-12-01), Schochetman et al.
patent: 4931544 (1990-06-01), Katre et al.
patent: 4963355 (1990-10-01), Kim et al.
patent: 5030717 (1991-07-01), Tramontano et al.
patent: 5037750 (1991-08-01), Schochetman et al.
patent: 5079152 (1992-01-01), Benkovic et al.
patent: 5187086 (1993-02-01), Janda et al.
patent: 5202270 (1993-04-01), Ungemach et al.
patent: 5463028 (1995-10-01), Landry et al.
Ambre, J., et al., (1984), Urinary excretion of ecgonine methyl ester, a major metabolite of cocaine in humans, J. Anal. Toxicol., 8:23-25 (Exhibit 17).
Ambre, J., (1985), The urinary excretion of cocaine and metabolites in humans: a kinetic analysis of published data, J. Anal. Toxicol., 9:241-245 (Exhibit 18).
Bach, J.F., et al., (1993), Safety and efficacy of therapeutic monoclonal antibodies in clinical therapy, Immunol. Today, 14:421-425 (Exhibit 19).
Baldwin, E., and Schultz, P.G., (1989), Generation of a catalytic antibody by site-directed metagenesis, Science, 245:1104-1107 (Exhibit 20).
Benkovic, S.J., (1988), Catalysis of a stereospecific bimolecular amide synthesis by an antibody, Proc. Natl. Acad. Sci. USA, 85:5355-5358.
Benkovic, S.J., et al., (1990), The enzymic nature of antibody catalysis: development of multistep kinetic processing, Science, 250:1135-1139 (Exhibit 22).
Benuck, M., et al., (1987), Pharmacokinetics of systemically administered cocaine and locomotor stimulation in mice, J. Pharmacol. Exp. Therap., 243:144-149 (Exhibit 23).
Bonese, K.F., et al., (1974), Changes in heroin self-administration by a rhesus monkey after morphine immunization, Nature, 252:708-710 (Exhibit 24).
Borrebaeck, C.A.K., (1989), Strategy for the production of human monoclonal antibodies using in vitro activated B cells, J. Immunol. Methods, 23:157-165 (Exhibit 25).
Carpenter, C.B., (1990), Immunosuppression in organ transplantation, N. Engl. J. Med., 332:1224-1226 (Exhibit 26).
Chandrakumar, N.S., et al., (1993), Phenylphosphonate monoester analogs of cocaine, Bioorg. & Medic. Chem. Let., 3:309-312 (Exhibit 27).
Chow, M.J., (1985), Kinetics of cocaine distribution, elimination, and chronotropic effects, Clin. Pharmacol. Ther., 38:318-324 (Exhibit 28).
Cochran, A.G., et al., (1991), Antibody-catalyzed biomolecular imine formation, J. Am. Chem. Soc., 113:6670-6672 (Exhibit 29).
Dean, R.A., et al., (1991), Human liver cocaine esterases: ethanol-mediated formation of ethylcocaine, FASEB J., 5:2753-2739 (Exhibit 30).
Fischman, M.W., et al., (1990), Effects of desipramine maintenance on cocaine self-administration by humans, J. Pharmacol. & Exp. Ther., 253:760-770 (Exhibit 31).
Fujii, I., et al., (1991), Enantiofacial protonation by catalytic antibodies, J. Am. Chem. Soc., 113:8528-8529 (Exhibit 32).
Gatley, S.J., et al., (1990) Rapid stereoselective hydrolysis of (+)-cocaine in baboon plasma prevents its uptake in the brain: implications for behavioral studies, J. Neurochem., 54:720-723 (Exhibit 33).
Gawin, F.H., et al., (1988), Cocaine and other stimulants: actions, abuse and treatment, New Eng. J. Med., 318:1173-1182 (Exhibit 34).
Gawin, F.H., et al., (1989), Desipramine facilitation of initial cocaine abstinence, Arch. Gen. Psychiatry, 46:117-121 (Exhibit 35).
Goeders, N.E., (1983), Cortical dopaminergic involvement in cocaine reinforcement, Science, 221:773-775 (Exhibit 37).
Harris, W.J., et al., (1993), Therapeutic antibodies--the coming of age, TIBTECH, 11:42-44 (Exhibit 38).
Ikeda, S., et al., (1991), Asymmetric induction via a catalytic antibody, J. Am. Chem. Soc., 113:7763-7764 (Exhibit 39).
Iverson, B.L. and Lerner, R.A., (1989), Sequence-specific peptide cleavage catalyzed by an antibody, Science, 243:1184-1188 (Exhibit 40).
Jackson, D.Y., et al., (1988), An antibody-catalyzed claisen rearrangement, J. Am. Chem. Soc., 110:4841-4842 (Exhibit 41).
Janda, K.D., et al., (1991), Catlytic antibodies with acyl-transfer capabilities: mechanistic and kinetic investigations, J. Am. Chem. Soc., 113:291-297 (Exhibit 42).
Janda, K.D., et al., (1988), Induction of an antibody that catalyzes the hydrolysis of an amide bond, Science, 241:1188-1191 (Exhibit 43).
Janda, K.D., et al., (1989), Catalytic antibodies with lipase activity and R or S substrate selectivity, Science, 244:437-440 (Exhibit 44).
Janda, K.D., et al., (1991), Antibody bait and switch catalysis: a survey of antigens capable of inducing abzymes, J. Am. Chem. Soc., 113:5427-5434 (Exhibit 45).
Janda, K.D., et al., (1991), Substrate attenuation: an approach to improve antibody catalysis, Tetrahedron, 47:2503-2506 (Exhibit 46).
Kitazume, T., et al., (1991), Antibody-catalyzed double stereoselection in fluorinated materials, J. Am. Chem. Soc., 113:8573-8575 (Exhibit 47).
Lesko, L.M., et al., (1982), Introgenous cocaine psychosis, New Eng. J. Med., 307:1153 (Exhibit 49).
Mayforth, R.D., et al., (1990), Designer and catalytic antibodies, N. Engl. J. Med., 323:173-178 (Exhibit 50).
Osband, M.E., et al., (1990), Problems in the investigational study and clinical use of cancer immunotherapy, Immunol. Today, 11:193-9195 (Exhibit 51).
Pollack, S.J., (1986), Selective chemical analysis by an antibody, Science, 234:1570-1573 (Exhibit 52).
Queen, C., et al., (1989), A humanized antibody that binds to the interleukin 2 receptor, Proc. Natl. Acad. Sci. USA, 86:10029-10033 (Exhibit 53).
Reichmann, L.M., et al., (1988), Reshaping human antibodies for therapy, Nature, 332:323-327 (Exhibit 54).
Robins, R.J., (1996), The measurement of low-molecular-weight, non-immunogenic compounds by immunoassay. In: H. Linskens and J.F. Jackson (Eds.), Immunology in Plant Sciences, Springer-Verlag, Berlin Heidelberg, pp. 86-141, (Exhibit 55).
Schultz, P.G., (1988), The interplay between chemistry and biology in the design of enzymatic catalysts, Science, 240:426-433 (Exhibit 56).
Seaver, S.S., (1994), Monoclonal antibodies in industry: more difficult than originally thought, Genetic Engineering News, 14:10, 21 (Exhibit 57).
Shokat, K.M., et al., (1989), A new strategy for the generation of catalytic antibodies, Nature, 338:269-271 (Exhibit 58).
Tramontano, et al., (1986), Catalytic antibodies, Science, 234:1566-1570 (Exhibit 59).
Tramontano, A., et al., (1986), Chemical reactivity at an antibody binding site elicited by mechanistic design of a synthetic antigen, Proc. Natl. Acad. Sci. USA, 83:6736-6740 (Exhibit 60).
Tramontano, A., et al., (1988), Antibody catalysis approaching the activity of enzymes, J. Am. Chem. Soc., 110:2282-2286 (Exhibit 61).
Waldman, T.A., (1991), Monoclonal antibodies in diagnosis and therapy, Science, 252:1657-1662 (Exhibit 62).
Ziegler, E.J., et al., (1991), Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin, N. Engl. J. Med., 324:429-436 (Exhibit 63).
National Institute On Drug Abuse "Development of immunological and molecular biological approaches to effect reduction of cocaine use." NIH Guide vol. 21, No. 34, Sep. 25, 1991.
National Institute On Drug Abuse "Development of innovative methods to identify medications for treating
Landry Donald W.
Zhao Kang
Hutzell Paula K.
The Trustees of Columbia University in the City of New York
Ungar Susan
White John P.
LandOfFree
Catalytic antibodies against cocaine does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Catalytic antibodies against cocaine, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Catalytic antibodies against cocaine will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2136933